Case studies

Two programs. Two stages.

Two active programs at different design stages. Every in-silico claim below has a defined, scheduled wet-lab readout that would confirm or falsify it — the validation plan is stated on each card. Figures are predictions and design targets, labelled as such throughout. Partnering now is how a collaborator gets in before that readout de-risks the asset.

P1 · Internal

In silico PoC

A trispecific TCE with conditional costimulation.

EpCAM tumor targeting × attenuated CD3 × 4-1BB conditional agonism. The third arm is designed as a costimulation gate intended to preferentially activate in the tumor microenvironment; conditional gating and anti-exhaustion efficacy require functional validation. Lead candidate assembled from validated EpCAM, CD3, and 4-1BB modules with stabilized G4S linkers.

Predicted Kd (EpCAM)

design target

Structural conf

in progress

Wet-lab status

Scheduled Q3 '26

IP status

In-licensed · Sch. B

Validation plan · how this de-risks
Next: SPR/BLI to confirm each arm's affinity, then a TDCC cell-killing assay on EpCAM⁺ lines and a 4-1BB functional-gate check. Readout: measured Kd per arm + tumor-cell kill + conditional-agonism confirmation. Scheduled Q3 '26. A single confirmed Kd converts the headline prediction to evidence.

P2 · Internal

In vitro PoC

A tumor-localized 4-1BB costimulator.

EpCAM tumor targeting × 4-1BB conditional costimulation × HSA half-life extension. The 4-1BB arm is designed to concentrate costimulation in EpCAM-positive tissue while limiting systemic exposure; conditional gating and selectivity require in-vitro and in-vivo validation. A human serum albumin (HSA) module extends serum half-life. No CD3 arm — this is a tumor-localized costimulator, not a T-cell engager.

Target Kd (EpCAM)

design target

Format

EpCAM × 4-1BB × HSA

In vivo

Q3 '26

IP status

In-licensed · Sch. B

Validation plan · how this de-risks
Next: SPR/BLI to confirm each arm's affinity, then an in-vitro 4-1BB functional-agonism assay on EpCAM⁺ lines, then a single-dose in-vivo PK/activity study. Scheduled Q3 '26. A measured affinity and functional-gate readout converts the design into evidence.

External case studies · publishing as partners sign off

The next three case-study slots are reserved for external partnerships. Public disclosure follows the partner's own announcement schedule.